Listed

Coherus Oncology, Inc.

CHRSNasdaqCIK 1512762HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$14.3mRevenue, Q2 FY2026, three months to 2026-06-30$14.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001104659-26-091262.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 5, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$14.3mRevenue, Q2 FY2026, three months to 2026-06-30$14.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001104659-26-091262.Report this figure+39.5% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin−226.0%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$32.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001104659-26-091262.Revenue: $14.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001104659-26-091262.Report this figure+217.6 pts on a year earlier
  • Net margin−144.2%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$20.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001104659-26-091262.Revenue: $14.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001104659-26-091262.Report this figure−3048.1 pts on a year earlier
  • Diluted EPS−$0.13Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.13 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001104659-26-091262.Report this figureSign changed from a year earlier
  • Free cash flownot reported (Capital expenditure not reported)No year-earlier figure to compare

Last eight quarters

Full statements
Revenue$14.3mOperating margin −226.0%
Diluted EPS−$0.13, Q2 FY2026
Coherus Oncology, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m6.1Revenue, Q3 FY2024, three months to 2024-09-30$6.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-06, accession 0001104659-25-107852.Report this figure7.7Revenue, Q4 FY2024, three months to 2024-12-31$7.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-09, accession 0001104659-26-025308. Derived: 12-month figure less the 9-month figure.Report this figure7.6Revenue, Q1 FY2025, three months to 2025-03-31$7.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-11, accession 0001104659-26-058703.Report this figure10.3Revenue, Q2 FY2025, three months to 2025-06-30$10.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001104659-26-091262.Report this figure11.6Revenue, Q3 FY2025, three months to 2025-09-30$11.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-06, accession 0001104659-25-107852.Report this figure12.7Revenue, Q4 FY2025, three months to 2025-12-31$12.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-09, accession 0001104659-26-025308. Derived: 12-month figure less the 9-month figure.Report this figure12.3Revenue, Q1 FY2026, three months to 2026-03-31$12.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-11, accession 0001104659-26-058703.Report this figure14.3Revenue, Q2 FY2026, three months to 2026-06-30$14.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001104659-26-091262.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(774.2%)Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: −$46.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107852.Revenue: $6.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-06, accession 0001104659-25-107852.Report this figure(586.9%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$45.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-09, accession 0001104659-26-025308. Derived: 12-month figure less the 9-month figure.Revenue: $7.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-09, accession 0001104659-26-025308. Derived: 12-month figure less the 9-month figure.Report this figure(597.9%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$45.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-11, accession 0001104659-26-058703.Revenue: $7.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-11, accession 0001104659-26-058703.Report this figure(443.6%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$45.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001104659-26-091262.Revenue: $10.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001104659-26-091262.Report this figure(383.1%)Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: −$44.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107852.Revenue: $11.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-06, accession 0001104659-25-107852.Report this figure(359.9%)Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: −$45.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-09, accession 0001104659-26-025308. Derived: 12-month figure less the 9-month figure.Revenue: $12.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-09, accession 0001104659-26-025308. Derived: 12-month figure less the 9-month figure.Report this figure(293.7%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$36.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-11, accession 0001104659-26-058703.Revenue: $12.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-11, accession 0001104659-26-058703.Report this figure(226.0%)Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$32.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001104659-26-091262.Revenue: $14.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001104659-26-091262.Report this figure
Net margin%(177.6%)Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: −$10.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107852.Revenue: $6.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-06, accession 0001104659-25-107852.Report this figure(655.6%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$50.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-09, accession 0001104659-26-025308. Derived: 12-month figure less the 9-month figure.Revenue: $7.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-09, accession 0001104659-26-025308. Derived: 12-month figure less the 9-month figure.Report this figure(744.4%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$56.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001104659-26-091262.Revenue: $7.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-11, accession 0001104659-26-058703.Report this figure2903.9%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: $297.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001104659-26-091262.Revenue: $10.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001104659-26-091262.Report this figure(307.1%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$35.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107852.Revenue: $11.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-06, accession 0001104659-25-107852.Report this figure(295.3%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$37.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-09, accession 0001104659-26-025308. Derived: 12-month figure less the 9-month figure.Revenue: $12.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-09, accession 0001104659-26-025308. Derived: 12-month figure less the 9-month figure.Report this figure(311.3%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$38.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001104659-26-091262.Revenue: $12.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-11, accession 0001104659-26-058703.Report this figure(144.2%)Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$20.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001104659-26-091262.Revenue: $14.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001104659-26-091262.Report this figure
Diluted EPS$ per share(0.09)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001104659-25-107852.Report this figurenot reported (Diluted EPS not reported)2.57Diluted EPS, Q1 FY2025, three months to 2025-03-31$2.57 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001104659-26-091262.Report this figure2.57Diluted EPS, Q2 FY2025, three months to 2025-06-30$2.57 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001104659-26-091262.Report this figure(0.31)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.31 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001104659-25-107852.Report this figurenot reported (Diluted EPS not reported)(0.28)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.28 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-11, accession 0001104659-26-058703.Report this figure(0.13)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.13 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001104659-26-091262.Report this figure
Free cash flow$mnot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$42.2mOperating margin −429.5%
Diluted EPS$1.43, FY2025
Free cash flow−$175.2m, FY2023
Coherus Oncology, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m327Revenue, FY2021, twelve months to 2021-12-31$326.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2024-03-15, accession 0001558370-24-003436.Report this figure211Revenue, FY2022, twelve months to 2022-12-31$211.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2025-03-17, accession 0001558370-25-003126.Report this figure257Revenue, FY2023, twelve months to 2023-12-31$257.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2025-03-17, accession 0001558370-25-003126.Report this figure26.4Revenue, FY2024, twelve months to 2024-12-31$26.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-09, accession 0001104659-26-025308.Report this figure42.2Revenue, FY2025, twelve months to 2025-12-31$42.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-09, accession 0001104659-26-025308.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(80.8%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −$263.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-03-15, accession 0001558370-24-003436.Revenue: $326.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2024-03-15, accession 0001558370-24-003436.Report this figure(121.7%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$256.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-17, accession 0001558370-25-003126.Revenue: $211.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2025-03-17, accession 0001558370-25-003126.Report this figure(79.0%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$203.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-17, accession 0001558370-25-003126.Revenue: $257.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2025-03-17, accession 0001558370-25-003126.Report this figure(756.6%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$199.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-09, accession 0001104659-26-025308.Revenue: $26.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-09, accession 0001104659-26-025308.Report this figure(429.5%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$181.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-09, accession 0001104659-26-025308.Revenue: $42.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-09, accession 0001104659-26-025308.Report this figure
Net margin%(87.9%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$287.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-03-15, accession 0001558370-24-003436.Revenue: $326.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2024-03-15, accession 0001558370-24-003436.Report this figure(138.2%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$291.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-17, accession 0001558370-25-003126.Revenue: $211.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2025-03-17, accession 0001558370-25-003126.Report this figure(92.5%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$237.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-17, accession 0001558370-25-003126.Revenue: $257.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2025-03-17, accession 0001558370-25-003126.Report this figure108.0%Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: $28.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-09, accession 0001104659-26-025308.Revenue: $26.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-09, accession 0001104659-26-025308.Report this figure398.4%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $168.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-09, accession 0001104659-26-025308.Revenue: $42.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-09, accession 0001104659-26-025308.Report this figure
Diluted EPS$ per share(3.81)Diluted EPS, FY2021, twelve months to 2021-12-31−$3.81 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-15, accession 0001558370-24-003436.Report this figure(3.76)Diluted EPS, FY2022, twelve months to 2022-12-31−$3.76 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-17, accession 0001558370-25-003126.Report this figure(2.53)Diluted EPS, FY2023, twelve months to 2023-12-31−$2.53 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-17, accession 0001558370-25-003126.Report this figure0.25Diluted EPS, FY2024, twelve months to 2024-12-31$0.25 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-09, accession 0001104659-26-025308.Report this figure1.43Diluted EPS, FY2025, twelve months to 2025-12-31$1.43 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-09, accession 0001104659-26-025308.Report this figure
Free cash flow$m(38.7)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$37.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-03-15, accession 0001558370-24-003436.Capital expenditure: $1.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-03-15, accession 0001558370-24-003436.Report this figure(243)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$241.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-17, accession 0001558370-25-003126.Capital expenditure: $2.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-03-15, accession 0001558370-24-003436.Report this figure(175)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$174.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-17, accession 0001558370-25-003126.Capital expenditure: $286.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-03-15, accession 0001558370-24-003436.Report this figurenot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

Coherus Oncology, Inc., open-market insider transactions
DateInsiderTransactionSharesReported priceValueFiling
2014-11-12Lilly Eli & CoFormer 10% Owner Purchase164,963$13.50$2.2mForm 4

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Coherus Oncology, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
Timothy G. Youngquist 2020 Irrevocable Trust2026-06-30$18.3m13,050,623Not compared
BlackRock, Inc.2026-06-30$16.8m12,003,316Added+1,638,242
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$8.3m5,949,490Added+496,728
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$5.2m3,685,567Added+563,989
SAMSARA BIOCAPITAL, LLC2026-06-30$4.8m3,428,571Unchanged
Kohlberg Kravis Roberts & Co. L.P.2026-06-30$4.2m3,036,076Unchanged
STATE STREET CORP2026-06-30$3.3m2,382,305Added+56,446
TWO SIGMA INVESTMENTS, LP2026-06-30$3.2m2,259,412Reduced−42,589
CM Management, LLC2026-06-30$2.9m2,100,000Unchanged
Alyeska Investment Group, L.P.2026-06-30$2.4m1,733,234Reduced−516,766

Recent filings

All 902 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Coherus Oncology, Inc., recent filings
FiledFormWhat it isAccession number
2026-10-2908:10 ET8-K7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits0001104659-26-119912
2026-08-2817:11 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001104659-26-103316
2026-08-1717:28 ET8-K7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits0001104659-26-097951
2026-08-1717:27 ET8-K1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits0001104659-26-097949
2026-08-0517:14 ET10-QQuarterly reportPeriod 2026-06-300001104659-26-091262
2026-08-0516:43 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001104659-26-091188
2026-06-1516:40 ET8-K4.01 Change of auditor; 9.01 Financial statements and exhibits0001104659-26-074090
2026-06-0108:30 ET8-K5.07 Shareholder vote results0001104659-26-068615
2026-05-1116:43 ET10-QQuarterly reportPeriod 2026-03-310001104659-26-058703
2026-05-1116:16 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001104659-26-058666

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 9, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1512762
Tickers
CHRS
Exchange
Nasdaq
SIC code
2836 Biological Products, (No Diagnostic Substances)
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Accelerated filer<br>Smaller reporting company
Former names
Coherus BioSciences, Inc. (to 2025-05-28); BioGenerics, Inc. (to 2012-01-03)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 08:11 ET. Listed shows no prices and gives no investment advice.